Photobiomodulation devices ("red light therapy") for vaginal use have grown in popularity since 2022. Marketing often positions them as alternative to estrogen — a misleading comparison.
What FDA approval means here
These devices are typically cleared under FDA "General Wellness" category — much lower bar than drug approval. They are NOT FDA-approved as treatments for vaginal atrophy or dyspareunia. Local vaginal estrogen (Estring, Vagifem, Estrace cream) IS FDA-approved for these indications with decades of evidence.
The actual evidence base
Small studies (most industry-funded) show modest symptom improvement in some users. Effect sizes are smaller and less reliable than vaginal estrogen in head-to-head comparisons (where they exist). NAMS does not list photobiomodulation as evidence-based first-line treatment.
When this could still make sense
For women with absolute contraindication to local estrogen (some breast cancer survivors, certain endometrial cancer histories), red-light devices may be one of few non-hormonal options worth discussing. For most women, FDA-approved local estrogen is more effective and less expensive for year.